Clinical Trials Logo

Filter by:
NCT ID: NCT06372639 Recruiting - Clinical trials for Post Traumatic Stress Disorder

Characterization and Modulation of Traumatic Memories in PTSD Patients Using TMS

Start date: February 23, 2022
Phase: N/A
Study type: Interventional

Characterization and modulation of traumatic memories in PTSD patients using TMS.

NCT ID: NCT06368024 Completed - Healthy Clinical Trials

Establishment of Delphi-MD Safety Performance and Reliability

Start date: November 28, 2023
Phase:
Study type: Observational

A retrospective analysis of collected datasets. In this study we aim to establish Delphi-MD's safety and performance reliability for assessment and monitoring of Transcranial Magnetic Stimulation (TMS) Evoked Potentials (TEPs) as neurophysiological measurements.

NCT ID: NCT06362174 Active, not recruiting - Crohn's Disease Clinical Trials

Capsule & Omics for pRedicting Exacerbation of Crohn's Disease

CORE-CD
Start date: February 7, 2023
Phase:
Study type: Observational

The research group have previously evaluated the benefit of serial consecutive capsule endoscopy as monitoring tool for Crohn's disease in remission, demonstrating its superior accuracy for disclosing inflammation and for prediction of flares in comparison to other diagnostic modalities such as magnetic resonance enterography and inflammatory biomarkers. Subsequently, deep learning algorithms had developed to provide excellent accuracy for identification and grading of ulcers and intestinal strictures on capsule endoscopy still images. The investigators will advance this knowledge using a parallel two-parts approach.

NCT ID: NCT06361225 Not yet recruiting - RUSH Protocol Clinical Trials

Routine Use of RUSH Protocol in the Intensive Care Unit

Start date: August 1, 2024
Phase:
Study type: Observational

The RUSH protocol has been used for several years for the rapid evaluation of a patient admitted to the emergency room with shock. Traditionally, its use was especially common in trauma victims, but later its use was extended to patients admitted to the emergency room with shock from any reason. The protocol includes rapid assessment with the guideness of ultrasound of heart contraction, assessment for pleural effusions, assessment of intra-abdominal blood (FAST), diagnosis of venous thrombosis (DVT), and rulling out hydronephrosis. It can also add a pupil size assessment and an evaluation of the gallbladder and bile ducts, as well as the size of the bladder. In intensive care, we use this protocol (or part of it) for the evaluation of a patient who is deteriorating in the ICU for an unknown reason . In some patients we use this protocol as a routine part of the physical examination as part of the daily patient evaluation. We would like to investigate whether the routine use of the RUSH protocol as part of the daily patient evaluation in the general intensive care unit will lead to any change in the patient's management.

NCT ID: NCT06360380 Not yet recruiting - Clinical trials for Chronic Heart Failure

Reducing Fluid Overload in Heart Failure Patients Using a Non-invasive, Renal Independent System

REFORM-HF
Start date: July 3, 2024
Phase: N/A
Study type: Interventional

The REFORM-HF study aims to test a new technology, AquaPass, designed to assist patients experiencing symptoms of fluid overload due to Heart Failure. Patients will wear a lightweight suit that helps remove excess fluids through their sweat. The investigators want to see if the AquaPass system can remove an additional 500mL of fluids during treatment, alongside patients' regular medications like diuretics. Participants will select if to be treated at their home or in the outpatient clinic.

NCT ID: NCT06358365 Completed - Clinical trials for Chronic Kidney Diseases

Enhancing Fluid Transfer Through the Skin, by Increased Sweat Rate, on Hemodialysis Patients

Start date: March 29, 2023
Phase: N/A
Study type: Interventional

To demonstrate safety and performance of AquaPass System for improving fluid balance in hemo-dialysis patients, by increasing fluid loss via the skin.

NCT ID: NCT06356311 Recruiting - Clinical trials for Gastroesophageal Cancer

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

Start date: May 3, 2024
Phase: Phase 3
Study type: Interventional

This study will compare how safe and effective sacituzumab tirumotecan is versus the treatment of physician's choice (TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumotecan is superior to TPC with respect to Overall Survival (OS).

NCT ID: NCT06353828 Active, not recruiting - Ulcerative Colitis Clinical Trials

Phase 2a Study to Evaluate IcBD-01 Enema in Active Ulcerative Colitis Patients

Start date: March 1, 2023
Phase: Phase 2
Study type: Interventional

Ulcerative proctitis can lead to considerable morbidity, and the available treatment options are limited. Cannabidiol (CBD), a non-psychotropic ingredient of Cannabis sativa, possesses potent immunomodulatory and anti-inflammatory properties as described in both acute and chronic animal models of inflammation, including IBD models. Based on positive safety and initial efficacy profiles of CBD found in IBD animal and clinical studies, the main aim of this study is to evaluate the safety, tolerability and efficacy of a novel enema formulation of CBD for the treatment of active ulcerative proctitis.

NCT ID: NCT06353386 Recruiting - Clinical trials for Prostatic Neoplasms, Castration-Resistant

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

Start date: May 20, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

Substudy 01A is part of a larger research study that is testing experimental treatments for metastatic castration-resistant prostate cancer (mCRPC). The larger study is the umbrella study (U01). The goal of substudy 01A is to evaluate the safety and efficacy of opevesostat-based treatment combinations, or as a single agent, in participants with mCRPC. This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to evaluate the safety and tolerability, and to establish a recommended Phase 2 dose (RP2D) for the opevesostat-based treatment combinations. There will be no hypothesis testing in this study.

NCT ID: NCT06350669 Not yet recruiting - Vestibular Disorder Clinical Trials

App-supported Vestibular Rehabilitation (RCT)

Start date: June 2024
Phase: N/A
Study type: Interventional

A randomized controlled trial to assess the efficacy of an app-assisted vestibular rehabilitation in increasing adherence to VR and treatment outcomes